0.6584

7.23% -0.0513

Vaxart Inc (VXRT)

Overview News Price History Option Chain Discussions Forecast Stock Split Dividend History

Vaxart Inc stock is currently priced at $0.6584, with a 24-hour trading volume of 1.91M. It has seen a -7.23% decreased in the last 24 hours and a -46.47% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.7227 pivot point. If it approaches the $0.6291 support level, significant changes may occur.

Previous Close:

$0.7097

Open:

$0.7

24h Volume:

1.91M

Market Cap:

$114.47M

Revenue:

$9.10M

Net Income/Loss:

$-82.47M

P/E Ratio:

-0.8663

EPS:

-0.76

Net Cash Flow:

$-72.32M

1W Performance:

-21.83%

1M Performance:

-46.47%

6M Performance:

+1.45%

1Y Performance:

-10.18%

1D Range:

$0.6331

$0.724

52W Range:

$0.53

$1.59

Vaxart Inc Stock (VXRT) Company Profile

Name

Vaxart Inc

Sector

Healthcare (1197)

Industry

Biotechnology (688)

Phone

650-550-3500

Address

395 Oyster Point Boulevard, Suite 405, South San Francisco, CA

Employee

Twitter

Next Earnings Date

2024-05-02

Latest SEC Filings

VXRT's Discussions on Twitter

Vaxart Inc Stock (VXRT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-29-21	Resumed	Jefferies	Buy
Nov-02-21	Initiated	Cantor Fitzgerald	Overweight
Jun-29-21	Downgrade	B. Riley Securities	Buy → Neutral
Jun-24-21	Initiated	Jefferies	Buy
Jun-11-21	Initiated	Piper Sandler	Overweight
Aug-12-20	Reiterated	H.C. Wainwright	Buy
Jul-13-20	Initiated	B. Riley FBR	Buy

View All

Vaxart Inc Stock (VXRT) Latest News

Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14

GlobeNewswire Inc.

VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy?

Zacks Investment Research

Vaxart Inc Stock (VXRT) Financials Data

Vaxart Inc (VXRT) Revenue 2024

VXRT reported a revenue (TTM) of $9.10 million for the quarter ending December 31, 2023, a +675.47% rise year-over-year.

Vaxart Inc (VXRT) Net Income 2024

VXRT net income (TTM) was -$82.47 million for the quarter ending December 31, 2023, a +23.47% increase year-over-year.

Vaxart Inc (VXRT) Cash Flow 2024

VXRT recorded a free cash flow (TTM) of -$72.32 million for the quarter ending December 31, 2023, a +30.71% increase year-over-year.

Vaxart Inc (VXRT) Earnings per Share 2024

VXRT earnings per share (TTM) was -$0.58 for the quarter ending December 31, 2023, a +30.95% growth year-over-year.

Vaxart, Inc., a clinical-stage company, focuses on developing oral recombinant vaccines based on its proprietary oral vaccine delivery platform. The company's platform delivers various recombinant protein antigens, such as those used in influenza, hepatitis B, and human papilloma virus (HPV) vaccines, as well as other recombinant vaccines. Its development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus, as well as a therapeutic vaccine for HPV. The company is headquartered in South San Francisco, California.